Concinnity Genetics secures £3m seed funding led by Eos Advisory to advance gene therapy safety
The Edinburgh spinout will use the capital to launch new programmes and establish its operational footprint.
Concinnity Genetics is an Edinburgh-based biotechnology company developing advanced control systems for cell and gene therapies.
Concinnity Genetics has secured £3m in seed funding to transition out of the University of Edinburgh and establish its commercial operations. The oversubscribed round was led by Eos Advisory, with participation from Scottish Enterprise, Old College Capital, and Maven Capital Partners. The capital will support the creation of three new therapeutic programmes and the further development of the company RNA-based control systems.
The spinout emerged from research by Professor Susan Rosser at the UKRI UK Centre for Mammalian Synthetic Biology. By combining synthetic biology with artificial intelligence, Concinnity aims to address key safety concerns in the biopharmaceutical sector, allowing treatments to regulate their own side effects after dosing.
From the founder
"We are so excited to be taking the next step in our spin-out journey and want to sincerely thank all the investors and supporters who have helped us make it happen. Our ambition is to be the go-to partner for gene control to make gene and cell therapies as safe as possible. This commitment from our investors, building on the ongoing support from Scottish Enterprise, speaks to the potential they see in our work, and we look forward to using the funding to further develop our technology."
Jessica Birt
CEO and Co-founder at Concinnity Genetics
Investor perspective
"Concinnity is a perfect fit for Eos’s focus on backing pioneering Scottish science, addressing a significant unmet need in gene therapy. By combining synthetic biology and AI-machine learning, the Concinnity technology has been described as the ‘holy grail for emerging gene therapies’, making such treatments both more effective and safer."
Andrew McNeill
Managing Partner, Eos Advisory
Use of funds
- 01Continue product development
- 02Scale operations
Investors
Categories
About the company
Concinnity Genetics
Concinnity Genetics builds artificial intelligence platforms to improve the safety of gene therapies.